These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27161687)

  • 1. OC-14 - Baseline D-dimer levels are predictive of recurrent venous thromboembolism (VTE) at 6 months in cancer patients with VTE treated with tinzaparin.
    Piatek CI; Tagawa ST; Wei-Tsai D; Hanna D; Weitz IC; O'Connell C; Rochanda L; Groshen S; Liebman HA
    Thromb Res; 2016 Apr; 140 Suppl 1():S174. PubMed ID: 27161687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
    Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
    JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin.
    Hyers TM; Spyropoulos AC;
    J Thromb Thrombolysis; 2007 Dec; 24(3):225-32. PubMed ID: 17334932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients.
    Lee AY; Bauersachs R; Janas MS; Jarner MF; Kamphuisen PW; Meyer G; Khorana AA;
    BMC Cancer; 2013 Jun; 13():284. PubMed ID: 23764005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OC-11 - Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism.
    Young A; Phillips J; Hancocks H; Hill C; Joshi N; Marshall A; Grumett J; Dunn JA; Lokare A; Chapman O
    Thromb Res; 2016 Apr; 140 Suppl 1():S172-3. PubMed ID: 27161683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial.
    Khorana AA; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Lee AY
    J Clin Oncol; 2017 Apr; 35(10):1078-1085. PubMed ID: 28029329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of recurrent thromboembolic events according to treatment duration in patients with superficial vein thrombosis treated with intermediate dose of tinzaparin.
    Karathanos C; Kakkos SK; Georgiadis G; Ioannou C; Vasdekis S; Chatzis D; Latzios P; Giannoukas AD;
    Phlebology; 2023 Apr; 38(3):141-149. PubMed ID: 36461172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization.
    Bullano MF; Willey V; Hauch O; Wygant G; Spyropoulos AC; Hoffman L
    J Manag Care Pharm; 2005 Oct; 11(8):663-73. PubMed ID: 16194130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venous thromboembolism in cancer patients.
    Deng A; Galanis T; Graham MG
    Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism.
    Jiménez D; Díaz G; Marín E; Vidal R; Sueiro A; Yusen RD
    Thromb Haemost; 2006 Mar; 95(3):562-6. PubMed ID: 16525588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OC-13 - Safe and effective use of direct oral anticoagulants (DOAC) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism.
    Ross JA; Miller M; Hernandez CR
    Thromb Res; 2016 Apr; 140 Suppl 1():S173-4. PubMed ID: 27161685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of venous thromboembolism with dalteparin therapy in multiple myeloma patients.
    Lee SE; Jeon YW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Kim M; Min CK
    Thromb Res; 2015 Nov; 136(5):974-9. PubMed ID: 26432650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients.
    Carrier M; Le Gal G; Cho R; Tierney S; Rodger M; Lee AY
    J Thromb Haemost; 2009 May; 7(5):760-5. PubMed ID: 19245418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical analysis of 20 pregnant women with venous thromboembolic disease].
    Sun P; Dong DN
    Zhonghua Fu Chan Ke Za Zhi; 2011 Dec; 46(12):911-6. PubMed ID: 22333281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism.
    Douketis J; Tosetto A; Marcucci M; Baglin T; Cushman M; Eichinger S; Palareti G; Poli D; Tait RC; Iorio A
    Ann Intern Med; 2010 Oct; 153(8):523-31. PubMed ID: 20956709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped.
    Palareti G; Legnani C; Cosmi B; Guazzaloca G; Pancani C; Coccheri S
    Thromb Haemost; 2002 Jan; 87(1):7-12. PubMed ID: 11848459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extensive evaluation of the instrumentation laboratory IL test D-Dimer immunoturbidimetric assay on the ACL 9000 determines the D-Dimer cutoff value for reliable exclusion of venous thromboembolism.
    Curtin N; Highe G; Harris M; Braunstein A; Demattia F; Coss L
    Lab Hematol; 2004; 10(2):88-94. PubMed ID: 15224764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D-dimer levels and risk of recurrent venous thromboembolism.
    Eichinger S; Minar E; Bialonczyk C; Hirschl M; Quehenberger P; Schneider B; Weltermann A; Wagner O; Kyrle PA
    JAMA; 2003 Aug; 290(8):1071-4. PubMed ID: 12941680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral anticoagulant therapy in venous thromboembolism.
    Cosmi B; Palareti G
    Semin Vasc Med; 2003 Aug; 3(3):303-14. PubMed ID: 15199464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight-adjusted tinzaparin for the prevention of venous thromboembolism after bariatric surgery.
    Tseng EK; Kolesar E; Handa P; Douketis JD; Anvari M; Tiboni M; Crowther MA; Siegal DM
    J Thromb Haemost; 2018 Oct; 16(10):2008-2015. PubMed ID: 30099852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.